Ascendis Pharma AS (NASDAQ: ASND) — Company Overview, News & Financial Data
Ascendis Pharma is a biopharmaceutical company using TransCon technology to develop therapies for unmet medical needs.
Ascendis Pharma AS
Ascendis Pharma AS is a biopharmaceutical company headquartered in Hellerup, Denmark, that utilizes its proprietary TransCon prodrug technology platform to develop therapeutics for rare endocrine diseases and oncology. The company's technology temporarily links an inert carrier to a parent drug, enabling controlled, sustained systemic exposure. Commercialized products include SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency and YORVIPATH (palopegteriparatide) for hypoparathyroidism in adults. Ascendis Pharma continues to advance additional clinical-stage development programs, including TransCon CNP for achondroplasia. The company operates administrative offices and research and development operations in Denmark, Germany, the United States, and across international markets.
Snapshot
Operations
Products and/or services of Ascendis Pharma AS
- Pediatric Growth Hormone Therapies: Sustained-release long-acting human growth hormone prodrugs administered weekly for pediatric patients with growth hormone deficiency, providing continuous systemic exposure to support height velocity and metabolic growth outcomes.
- Hypoparathyroidism Treatments: Parathyroid hormone replacement prodrug therapies designed for daily subcutaneous administration to restore physiological hormone levels and maintain serum calcium balance in adults diagnosed with chronic hypoparathyroidism.
- Achondroplasia Therapies: Clinical-stage C-type natriuretic peptide prodrug therapeutics administered once weekly to stimulate linear bone growth and improve skeletal proportions in pediatric patients affected by achondroplasia.
- TransCon Prodrug Technology Platform: Proprietary drug delivery systems incorporating an unmodified parent drug, an inert carrier, and a chemical linker to enable predictable, sustained systemic release of therapeutics across multiple disease areas.
- Oncology Clinical Programs: Sustained-release cancer therapeutics combining systemic and intratumoral prodrug formulations designed to maximize local drug exposure, activate antitumor immune responses, and limit systemic toxicity in advanced solid tumors.
- Global Commercial Distribution: Integrated commercial supply chain, market access, and medical affairs infrastructure delivering endocrinology and rare disease therapeutics across major pharmaceutical markets in North America, Europe, and Asia-Pacific.
Ascendis Pharma AS executive team
- Jan Moller MikkelsenPresident, CEO, Member of Executive Board & Executive Director
- Scott T. SmithCFO, Executive VP & Member of Executive Board
- Pedersen Anni Lotte Kirstine SonderbjergExecutive VP, Chief Administrative Officer & Member of the Executive Board
- Michael Wolff JensenExecutive VP, Chief Legal Officer & Member of the Executive Board
- Mads BodenhoffSenior VP, Head of Finance & Principal Accounting Officer
- Chad FugureVice President of Investor Relations
- Flemming Steen JensenExecutive Vice President of Product Supply & Quality
- Kennett SprogoeExecutive VP and Head of Research & Product Development
- Joseph KellyHead of U.S. Commercial of Endocrinology
- Jay Donovan WuExecutive VP & President of Ascendis US
Latest news about Ascendis Pharma AS
Key financials
Reported results for Ascendis Pharma AS, in EUR.
- Market cap
- 16.4B
- Revenue (TTM)
- 1B
- P/E ratio
- 19.1
- EPS (diluted, TTM)
- 13.1
- Dividend yield
- —
- Profit margin
- 70.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 691.7M | -130.9M | -219M | |
| 363.6M | -278.8M | -378.1M | |
| 266.7M | -455.5M | -481.4M | |
| 51.2M | -561.8M | -583.2M |